Vaginal Estradiol Real-World Response Rate: What Patients Actually Experience

What kind of response data exist?

The evidence here is a placebo-controlled trial of one vaginal tablet and one head-to-head comparison of a ring with a cream. Both report mean score changes and group comparisons, not the share of women who responded.

What the 10-microgram tablet trial measured

Simon and colleagues randomized 309 postmenopausal women to a 10-microgram estradiol vaginal tablet or placebo for 52 weeks in a multicenter, double-blind study [1]. At week 12, compared with placebo:

• Parabasal cells changed by -37% versus -9%, superficial cells by 13% versus 4%, and intermediate cells by 24% versus 5% (P<0.001 for each) [1].
• Vaginal pH grade fell 1.3 versus 0.4, and maturation value rose 25.0 versus 6.5 (P<0.001 for each) [1].
• The most bothersome urogenital symptom score fell 1.23 versus 0.87 (P=0.003) [1].

There were no major safety findings on physical, gynecologic or laboratory assessment [1]. The tissue measures separated widely from placebo; the symptom score separated by less than half a point. Cytology, maturation and pH differed from placebo after 2 weeks, the symptom effect became apparent after 4 weeks and reached statistical significance at week 8, and all treatment effects were significant at week 52 [1].

Ring versus cream

A second trial randomized 194 postmenopausal women 2:1 to an estradiol-releasing vaginal ring or a conjugated equine estrogen cream for 12 weeks, open-label [2]. The two were equivalent for relief of vaginal dryness and dyspareunia, resolution of atrophic signs, maturation indices and pH reduction, and the ring was rated more acceptable (P<0.0001) and preferred (P<0.001) [2]. The comparison cream was a conjugated estrogen cream, not an estradiol cream.

What the vaginal cream label describes

The estradiol vaginal cream 0.01% label covers moderate to severe symptoms of vulvar and vaginal atrophy due to menopause. It gives a usual dosage of 2 to 4 g daily for one or two weeks, then gradually reduced to half the initial dose for a similar period, with a maintenance dose of 1 g one to three times a week once the vaginal mucosa has been restored [3].

The label states that systemic absorption may occur and that the warnings, precautions and adverse reactions associated with oral estrogen treatment should be taken into account [3]. It carries a boxed warning covering endometrial cancer, cardiovascular disorders, breast cancer and probable dementia [3]. Listed reactions include application-site vulvovaginal discomfort including burning and irritation, vaginitis including vaginal candidiasis, breast tenderness and headache [3].

For context, the 2020 NAMS statement estimates GSM affects roughly 27% to 84% of postmenopausal women and notes that long-term endometrial safety studies of vaginal estrogen are lacking [4].